Marshall Wace North America’s SpringWorks Therapeutics SWTX Stock Holding History

Marshall Wace North America’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$10.6M	Buy	167,171 +140,114	+518%	+$10.8M	0.05%	339
2021 Q2	$2.23M	Buy	+27,057	New	+$2.05M	0.01%	774
2020 Q4	–	Sell	-19,752	Closed	-$942K	–	1573
2020 Q3	$942K	Buy	+19,752	New	+$841K	0.01%	823
2019 Q4	–	Sell	-35,761	Closed	-$775K	–	1586
2019 Q3	$775K	Buy	+35,761	New	+$845K	﹤0.01%	740

Other funds holding SWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marshall Wace North America's SWTX Position: Q3 2021 in Review

Marshall Wace North America increased its SpringWorks Therapeutics (SWTX) stake by 518% in Q3 2021, buying an estimated $10.8M and bringing the position to 167,171 shares worth $10.6M. The position accounts for 0.05% of the portfolio, ranked #339.

Marshall Wace North America first reported a position in SWTX in Q3 2019 and has held it in 4 quarters since. 142 funds tracked by Wall St. Rank hold SWTX as of Q3 2021.

Marshall Wace North America held 167,171 shares of SpringWorks Therapeutics worth $10.6M as of Q3 2021.
Marshall Wace North America bought 140,114 SpringWorks Therapeutics shares in Q3 2021, an estimated $10.8M.
SpringWorks Therapeutics made up 0.05% of Marshall Wace North America's portfolio in Q3 2021, its #339 holding.
Marshall Wace North America first reported a position in SpringWorks Therapeutics in Q3 2019 and has held it in 4 quarters since.
142 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.